Clinical Trials

Probiodrug has reported positive results for its PQ912 candidate in a Phase 2a SAPHIR study in early Alzheimer’s disease (AD) patients. The SAPHIR study is the first clinical trial…
Read More...

Generon Corporation announced the initiation of a clinical trial for A-337, a CD3-activating bi-specific antibody targeting EpCAM, in Australia. This is a “Phase I, Open-label,…
Read More...

LEO Pharma today announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that…
Read More...

Astellas Pharma Inc. and Pfizer Inc. announced the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study…
Read More...

Sanofi and Regeneron Pharmaceuticals, Inc. announced positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes. In the studies, Praluent® (alirocumab), when…
Read More...

AbbVie Inc said on Wednesday its oral rheumatoid arthritis drug succeeded in a late-stage study on patients who had not adequately responded to standard treatments. The drug,…
Read More...

Sanofi and Regeneron Pharmaceuticals announced positive preliminary results with investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1), in patients with…
Read More...

BioCryst Pharmaceuticals announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial…
Read More...

Array BioPharma and Bristol-Myers Squibb Company announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of…
Read More...

Synthetic Genomics and Advaxis announced that they have completed development and deployment of the first current good manufacturing practice (cGMP) synthetic biology facility for the…
Read More...

Hovione announced that it will soon initiate recruitment for its Phase 1 clinical trial of HY02. This first in human study is a double-blinded, randomized trial, which will include…
Read More...

X4 Pharmaceuticals announced dosing of the first patient in the Phase 2 portion of the ongoing Phase 1/2 study evaluating X4P-001, the CXCR4 inhibitor, in combination with Inlyta…
Read More...

TrialScope has announced the launch its second Clinical Trial Disclosure Maturity Survey for clinical trial sponsors to perform self-assessments of their disclosure practices. The…
Read More...

Atox Bio announced that Reltecimod (previously AB103) successfully completed pre-specified futility analysis in patients with Necrotizing Soft Tissue Infections and will continue…
Read More...

Debiopharm International SA and ImmunoGen announced that Debiopharm has acquired ImmunoGen's IMGN529/Debio 1562, a clinical-stage anti-CD37 ADC (antibody-drug conjugates) for the…
Read More...

Worldwide Clinical Trials has appointed Karen Nowatkoski as Vice President of Clinical Operations and Site Management. She will oversee and provide global management for the team of…
Read More...

PCI Biotech and RXi Pharmaceuticals announced that they are extending their preclinical research collaboration initiated on April 7, 2015. The preclinical research collaboration will…
Read More...

Sanofi announced that the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) recommended the use of Insulin lispro Sanofi (insulin lispro 100…
Read More...

Pharmaceutical Product Development (PPD) has expanded its vaccine sciences lab in Richmond, Virginia, to enhance its ability so as to provide industry-leading capabilities to meet…
Read More...

Aduro Biotech announced the expansion of its clinical collaboration with Merck to include an additional Phase 2 clinical trial to evaluate the combination of CRS-207, Aduro’s LADD…
Read More...